Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
M & A Business Strategies Deals

Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

  • Analysis

Executive Summary

Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.

You may also be interested in...



Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.

Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri

The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
M & A Business Strategies Deals
Latest Headlines

BIO Notebook: GSK’s Walmsley On M&A; Merck On How Falling Valuations Are Affecting Deals

ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats

ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill

ASCO 2023 – Bicara Eyes Head And Neck Niche

See All
UsernamePublicRestriction

Register

SC145213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By